Description
VITARAN II is a CE‑marked polynucleotide (PDRN) injectable from the VITARAN range by Fox Pharma. It contains purified trout (salmon‑trout) DNA fragments — polynucleotide sodium at 20 mg/ml (PN 2%) — formulated to act as a bio‑revitalising agent rather than a volumising filler.
As a regenerative skin booster, VITARAN II aims to stimulate dermal repair and cellular regeneration by promoting fibroblast activity, collagen and elastin synthesis, improving skin elasticity, hydration, and overall skin quality.
VITARAN II is indicated for addressing skin ageing signs — including decreased elasticity, fine lines, uneven texture, skin laxity, and dullness — across larger skin areas (e.g., face, neck, décolletage, hands, and body).
What VITARAN II Is Similar To
VITARAN II belongs to the category of polynucleotide (PDRN) skin boosters rather than traditional hyaluronic acid (HA) fillers. For clinical orientation, it can be compared to other “skin‑revitalizing” injectables (or mesotherapy / booster products) that aim to improve skin quality, texture, and dermal regeneration rather than volume restoration.
Unlike HA fillers — which add structural volume, contour, and fill deep wrinkles — VITARAN II works by stimulating fibroblasts, encouraging collagen and elastin synthesis, improving skin elasticity, and enhancing hydration. Compared to lighter skin‑boosters or superficial serums, VITARAN II — with its sterile injectable format and relatively high PDRN concentration — potentially offers deeper, more uniform dermal delivery and broader treatment area coverage (face, neck, hands, décolletage).
This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
According to the manufacturer’s public information, VITARAN II is indicated for use on:
-
Face
-
Neck
-
Décolletage (chest)
-
Hands
-
Body (larger skin areas)
Usage / Administration (IFU‑only section)
-
Injection depth / method: not provided by manufacturer in publicly available documentation.
-
Needle gauge / supplied needle: 33 G sterile needle per syringe.
-
Volume per point / injection site: not provided by manufacturer.
-
Frequency / number of sessions: not specified in publicly accessible data. One distributor lists general schedule of “2–3 sessions” as typical for skin‑booster treatments, spaced 3–4 weeks apart — but this is not part of an official IFU.
-
Professional‑use disclaimer: The product is supplied only to qualified aesthetic practitioners — use requires relevant skin‑booster (polynucleotide) certification.
Because the publicly available documentation lacks a full IFU with detailed protocol (depth, dose per injection, session schedule), practitioners must consult the official IFU supplied with VITARAN II for final administration parameters.
Ingredient List
-
Polynucleotide sodium (PDRN) — 20 mg/ml (PN 2%)
-
Buffer / solvent (q.s.) — composition details not publicly specified.
No hyaluronic acid, lidocaine, or cross‑linked HA gel matrix is declared for this product in publicly available sources.
Presentation & Longevity
-
Packaging: 2 × 2 ml sterile syringes, each supplied with a 33 G needle.Shelf-life / expiry: not provided in public documentation.
-
Expected duration of effect: not explicitly stated by manufacturer — as a regenerative skin booster, the duration depends on individual skin response, treatment protocol, and post-care; no fixed longevity claim is available.
Safety Notes / Contraindications
Public product pages for VITARAN II do not present a full IFU-based list of contraindications. Based on standard practice for polynucleotide injectables / skin boosters (and by analogy with the company’s “Eyes” and “I” formulations), the following precautions should be considered:
-
Use only by qualified practitioners under aseptic conditions.
-
Avoid use in patients with known hypersensitivity to PDRN or any formulation component (e.g., fish‑derived DNA).
-
Avoid treating active skin infections, inflammatory skin conditions, or compromised skin barrier at injection site.
-
Caution in patients with immune disorders, on immunosuppressive or blood‑thinning therapies, or prone to keloid formation (common caution for injectables).
Standard caution applies: “Use is contraindicated in patients with known hypersensitivity to any component or with active skin infections at the injection site.”
Regulatory Status
-
VITARAN II is listed as a CE‑marked medical‑aesthetic polynucleotide injectable.
-
Public documentation does not explicitly confirm UKCA marking — practitioners should verify regulatory labeling on product packaging or IFU before use in UK.
FAQ
Q1: How does VITARAN II work to improve skin quality?
A1: VITARAN II contains polynucleotide (PDRN) fragments derived from purified trout DNA. Once injected into the dermis, PDRN is believed to stimulate fibroblast activity, enhance collagen and elastin synthesis, and support extracellular matrix remodeling — promoting dermal regeneration, improved elasticity, hydration, and skin quality rather than volume augmentation.
Q2: Will VITARAN II act like a dermal filler and add volume?
A2: No. VITARAN II is a bio‑revitalising skin booster, not a volumising filler. It does not contain cross‑linked hyaluronic acid gel or a volumising matrix. Its effect is regenerative — improving skin texture, firmness, elasticity, and hydration — rather than structural volume or contour.
Q3: Which areas can be treated with VITARAN II?
A3: Publicly indicated treatment areas for VITARAN II include face, neck, décolletage (chest), hands, and body (for larger skin zones) — making it suitable for clients seeking full‑face rejuvenation, skin tightening, or skin‑quality improvement over broad areas.
Q4: What is the standard treatment protocol with VITARAN II?
A4: Official publicly accessible data do not provide a detailed injection protocol (depth, dose per site, or frequency). Some suppliers recommend courses of 2–3 sessions spaced 3–4 weeks apart for optimal skin‑booster results — though this is not part of a verified IFU. Clinicians must refer to the official IFU supplied with the product for precise guidance.
Q5: What safety considerations apply to VITARAN II?
A5: As with all injectables, VITARAN II should be administered only by qualified professionals under aseptic conditions. It should not be used in patients with known hypersensitivity to PDRN, fish‑derived DNA, or any component of the formulation. Treatment should be avoided in areas with active skin infections or inflammation. For patients with immune compromise, bleeding disorders, or on immunosuppressive/anticoagulant therapy — a careful risk assessment is advised.
